drugset / Trial / NCT04683237
Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia
RandomizedParallel-groupOpen-labelTreatment
Summary
To investigate the efficacy of liraglutide plus megestrol acetate in obesity patients with atypical endometrial hyperplasia (AEH)
Timeline
- Start
- 2021-03-20
- Primary completion
- 2025-11-30
- Completion
- 2026-11-30
Outcome
Outcome not reported
Stopped (Enrollment): “Based on our latest research results, we will revise the protocol and design a better study. Since no participants are enrolled till now, we withdraw this study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liraglutide | Peptide | 1.8 mg | — |
| Subject | Megestrol Acetate | Other / unclassified | 160 mg | Oral |